These data suggest that pioglitazone, a thiazolidinedione that is an insulin sensitizer by activating PPARγ, should be used more widely for cardiovascular prevention in high-risk patients, especially those with a history of stroke [32, 37]. The gene discussed is PPARG; the disease is stroke disorder.